Hardan I - Search Results

1

Chromosome 13q deletion and IgH abnormalities may be both masked by near-tetraploidy in a high proportion of multiple myeloma patients: a combined morphology and I-FISH analysis.

Koren-Michowitz M, Hardan I, Berghoff J, Yshoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. Koren-Michowitz M, et al. Among authors: hardan i. Cancer Lett. 2007 Oct 8;255(2):307-14. doi: 10.1016/j.canlet.2007.05.005. Epub 2007 Jun 27. Cancer Lett. 2007. PMID: 17590504

2

Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma.

Palumbo A, Gay F, Cavallo F, Di Raimondo F, Larocca A, Hardan I, Nagler A, Petrucci MT, Hajek R, Pezzatti S, Delforge M, Patriarca F, Donato F, Cerrato C, Nozzoli C, Yu Z, Boccadifuoco L, Caravita T, Benevolo G, Guglielmelli T, Vincelli D, Jacques C, Dimopoulos MA, Ciccone G, Musto P, Corradini P, Cavo M, Boccadoro M. Palumbo A, et al. Among authors: hardan i. J Clin Oncol. 2015 Oct 20;33(30):3459-66. doi: 10.1200/JCO.2014.60.2466. Epub 2015 Aug 17. J Clin Oncol. 2015. PMID: 26282661 Free article. Clinical Trial.

3

Correlation between losses of IGH or its segments and deletions of 13q14 in t(11;14) (q13;q32) multiple myeloma.

Trakhtenbrot L, Hardan I, Koren-Michowitz M, Oren S, Yshoev G, Rechavi G, Nagler A, Amariglio N. Trakhtenbrot L, et al. Among authors: hardan i. Genes Chromosomes Cancer. 2010 Jan;49(1):17-27. doi: 10.1002/gcc.20716. Genes Chromosomes Cancer. 2010. PMID: 19787791

4

The high-affinity CXCR4 antagonist BKT140 is safe and induces a robust mobilization of human CD34+ cells in patients with multiple myeloma.

Peled A, Abraham M, Avivi I, Rowe JM, Beider K, Wald H, Tiomkin L, Ribakovsky L, Riback Y, Ramati Y, Aviel S, Galun E, Shaw HL, Eizenberg O, Hardan I, Shimoni A, Nagler A. Peled A, et al. Among authors: hardan i. Clin Cancer Res. 2014 Jan 15;20(2):469-79. doi: 10.1158/1078-0432.CCR-13-1302. Epub 2013 Nov 18. Clin Cancer Res. 2014. PMID: 24246358 Clinical Trial.

5

Allogenic hematopoietic stem-cell transplantation with reduced-intensity conditioning in patients with refractory and recurrent multiple myeloma: long-term follow-up.

Shimoni A, Hardan I, Ayuk F, Schilling G, Atanackovic D, Zeller W, Yerushalmi R, Zander AR, Kroger N, Nagler A. Shimoni A, et al. Among authors: hardan i. Cancer. 2010 Aug 1;116(15):3621-30. doi: 10.1002/cncr.25228. Cancer. 2010. PMID: 20564132

6

Translocation t(11;14) in newly diagnosed patients with multiple myeloma: Is it always favorable?

Leiba M, Duek A, Amariglio N, Avigdor A, Benyamini N, Hardan I, Zilbershats I, Ganzel C, Shevetz O, Novikov I, Cohen Y, Ishoev G, Rozic G, Nagler A, Trakhtenbrot L. Leiba M, et al. Among authors: hardan i. Genes Chromosomes Cancer. 2016 Sep;55(9):710-8. doi: 10.1002/gcc.22372. Epub 2016 Jun 24. Genes Chromosomes Cancer. 2016. PMID: 27152944

7

Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.

Besser MJ, Shapira-Frommer R, Treves AJ, Zippel D, Itzhaki O, Hershkovitz L, Levy D, Kubi A, Hovav E, Chermoshniuk N, Shalmon B, Hardan I, Catane R, Markel G, Apter S, Ben-Nun A, Kuchuk I, Shimoni A, Nagler A, Schachter J. Besser MJ, et al. Among authors: hardan i. Clin Cancer Res. 2010 May 1;16(9):2646-55. doi: 10.1158/1078-0432.CCR-10-0041. Epub 2010 Apr 20. Clin Cancer Res. 2010. PMID: 20406835 Clinical Trial.

8

Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using combined morphologic and fluorescence in situ hybridization analysis.

Hardan I, Rothman R, Gelibter A, Cohen N, Shimoni A, Sokolovsky M, Reichart M, Ishoev G, Amariglio N, Rechavi G, Nagler A, Trakhtenbrot L. Hardan I, et al. Exp Hematol. 2004 Mar;32(3):254-60. doi: 10.1016/j.exphem.2003.12.001. Exp Hematol. 2004. PMID: 15003310

9

Feasibility and low toxicity of early radiotherapy after high-dose chemotherapy and autologous stem cell transplantation for patients with high-risk stage II-III and locally advanced breast carcinoma.

Stemmer SM, Pfeffer MR, Rizel S, Hardan I, Goffman J, Gezin A, Neumann A, Kitsios P, Alezra D, Brenner HJ. Stemmer SM, et al. Among authors: hardan i. Cancer. 2001 Jun 1;91(11):1983-91. Cancer. 2001. PMID: 11391576 Clinical Trial.

10

Extramedullary progression despite a good response in the bone marrow in patients treated with thalidomide for multiple myeloma.

Avigdor A, Raanani P, Levi I, Hardan I, Ben-Bassat I. Avigdor A, et al. Among authors: hardan i. Leuk Lymphoma. 2001 Aug;42(4):683-7. doi: 10.3109/10428190109099330. Leuk Lymphoma. 2001. PMID: 11697498

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results